John Lally
About John Lally
John Lally is the VP, Head of Pharmaceutical Development at Alkermes, with over 39 years of experience in the pharmaceutical and biotechnology industries.
Current Role at Alkermes
John Lally is currently the Vice President, Head of Pharmaceutical Development at Alkermes. Bringing over 39 years of extensive experience in the pharmaceutical and biotechnology industries, he plays a key role in overseeing and guiding the development of pharmaceutical products. His background and expertise support Alkermes' mission to develop innovative medicines.
Previous Positions at Alkermes
Before his current role, John Lally served as Vice President of Regulatory Affairs CMC at Alkermes from 2018 to 2023. Prior to that, he held the position of Senior Director of Regulatory Affairs CMC from 2013 to 2018. His roles at Alkermes primarily focused on regulatory strategies and compliance in Chemistry, Manufacturing, and Controls (CMC), demonstrating his leadership in ensuring regulatory adherence and quality standards.
Global Experience at AstraZeneca
John Lally acquired significant international experience while working at AstraZeneca. Between 2000 and 2003, he was the Director of Global R&D GMP Systems in Sodertalje, Sweden. Previously, from 1998 to 2000, he held the position of Senior Manager for Quality Assurance & Quality Compliance in Westborough, MA. This global exposure provided him with valuable insights into regulatory frameworks across different regions, contributing to his holistic understanding of the industry.
Early Career at Center for Blood Research & IMB Pharma, Inc.
John Lally began his career in the pharmaceutical industry at the Center for Blood Research & IMB Pharma, Inc. He worked in various roles from 1984 to 1995 in Boston and Worcester, MA. This early experience laid the foundation for his extensive career, allowing him to develop a deep understanding of the industry's technical and regulatory aspects.
Educational Background in Biotechnology
John Lally holds a Bachelor of Science (BS) in Biotechnology from Worcester Polytechnic Institute, where he studied from 1980 to 1984. His educational background in biotechnology provided the technical knowledge necessary for his extensive career in pharmaceutical and biotechnology sectors.